BioCentury
ARTICLE | Clinical News

Dendreon takes Provenge earlier in prostate cancer

May 25, 2018 6:23 PM UTC

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer.

Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and an immunostimulatory cytokine. It is approved to treat metastatic castration-resistant prostate cancer (CRPC)...